Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.085 | 0.7 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.079 | 0.7 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |